RedHill Biopharma Ltd (ADR) (OQ:RDHL)
Business Focus: Biopharmaceuticals
May 06, 2024 07:00 am ET
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intellectual property portfolio across multiple indications
Apr 24, 2024 07:00 am ET
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early COVID-19 outpatient treatment, funded through non-dilutive external sources, including the U.S. Department of Defense
Apr 08, 2024 09:00 am ET
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base
Apr 02, 2024 07:00 am ET
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
TEL AVIV, Israel and RALEIGH, N.C., April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 per ADS and accompanying warrant,
Feb 20, 2024 06:00 am ET
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation
Jan 26, 2024 11:46 am ET
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 26, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 10,000,000 ADSs. The warrants have an exe
Jan 25, 2024 08:05 am ET
RedHill Biopharma Announces $8 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 25, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS, in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up t
Jan 25, 2024 05:00 am ET
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
USPTO issues new patent covering Talicia[1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI)[2], supporting Talicia protection until May 2042
Jan 24, 2024 08:31 am ET
Thinking about buying stock in Kura Oncology, UiPath, C3.ai, Crowdstrike, or RedHill Biopharma?
NEW YORK, Jan. 24, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KURA, PATH, AI, CRWD, and RDHL.
Dec 20, 2023 07:45 am ET
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viability, in a new U.S. Army-funded and conducted in vitro Ebola virus study
Dec 12, 2023 06:00 am ET
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
TEL AVIV, ISRAEL and RALEIGH, N.C., Dec. 12, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing
Dec 04, 2023 08:31 am ET
Thinking about buying stock in Broadcom, Bitfarms, RedHill Biopharma, Garden Stage, or Virgin Galactic Holdings?
NEW YORK, Dec. 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGO, BITF, RDHL, GSIW, and SPCE.
Dec 04, 2023 06:00 am ET
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
The new non-dilutive external funding, additional to the previously announced U.S. Government non-dilutive funding, now covers the entirety of the RHB-107 (upamostat)[1] arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment
Nov 29, 2023 08:31 am ET
Thinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?
NEW YORK, Nov. 29, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RDHL, MYNA, ET, SEEL, and WOOF.
Nov 27, 2023 06:00 am ET
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
The U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by the FDA Exclusivity Board
Nov 14, 2023 07:00 am ET
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
TEL AVIV, Israel & RALEIGH, N.C., Nov. 14, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") to transfer the listing of the American Depositary Shares ("ADSs") to the Nasdaq Capital Market. The ADSs will be transferred to the Nasdaq Capital Market at the opening of business on November 15, 2023.
Oct 17, 2023 09:31 am ET
Thinking about buying stock in Momentus Inc, Secoo Holding, RedHill Biopharma, Aldeyra Therapeutics, or Mereo BioPharma Group?
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNTS, SECO, RDHL, ALDX, and MREO.
Oct 04, 2023 09:31 am ET
Thinking about buying stock in ALX Oncology Holdings, RedHill Biopharma, Freeline Therapeutics Holdings, Terawulf, or I-Mab?
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALXO, RDHL, FRLN, WULF, and IMAB.
Oct 03, 2023 07:00 am ET
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
- Novel, oral opaganib, delivered a statistically significant increase in survival time (at 150 mg/kg BID) in a U.S. Army-funded in vivo Ebola virus study
Sep 22, 2023 04:15 pm ET
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
TEL AVIV, Israel & RALEIGH, N.C., Sept. 22, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the thirty consecutive business days from August 7, 2023, to September 18, 2023, the bid price for the Company's American Depositary Shares ("ADSs") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global M
Sep 18, 2023 07:00 am ET
RedHill Announces FDA sNDA Approval for Talicia®
FDA approves supplemental new drug application (sNDA) for Talicia, changing dosing to a simplified three times daily (TID) regimen, which may support increased patient adherence and treatment outcomes
Aug 01, 2023 07:00 am ET
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group (GAG), receives marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia
Jul 31, 2023 07:00 am ET
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
RHB-107 (upamostat) accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa
Jul 25, 2023 03:58 pm ET
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
TEL AVIV, ISRAEL, and RALEIGH, N.C., July 25, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,301,923 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent).
Jul 21, 2023 09:33 am ET
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
TEL AVIV, ISRAEL & RALEIGH, N.C., July 21, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 1,301,923 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a registered direct offering.
Jul 21, 2023 07:00 am ET
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
Opaganib awarded a further $1.7 million in U.S. Government funding for development as a medical countermeasure for gastrointestinal acute radiation syndrome (ARS)
Jun 12, 2023 08:00 am ET
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
Q1/23 Talicia net revenues of $3.4 million; Cash balance of $28.8 million as of March 31, 2023[1]; Extinguishment of all debt obligations in exchange for the transfer of rights in Movantik®[2] resulting in net income of $50.2 million for the first quarter of 2023
May 22, 2023 07:00 am ET
RedHill Provides R&D Update
RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatment of COVID-19
May 15, 2023 06:17 pm ET
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
TEL AVIV, Israel and RALEIGH, N.C., May 15, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated May 9, 2023 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares ("MVPHS") set forth in the Nasdaq Rules for continued Nasdaq listing.
May 09, 2023 07:00 am ET
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
New Talicia PBPK modeling data, published in AP&T Journal, showed that generically substituted regimens are non-bioequivalent to Talicia
May 01, 2023 07:00 am ET
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
European Patent Office grants RHB-102 patent covering antiemetic extended-release solid dosage forms for the prevention of nausea and vomiting (CINV/RINV), providing protection of RHB-102 to March 2034
Apr 28, 2023 07:00 am ET
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with U.S. and other governments, commercial growth and revenue-generating product acquisition opportunities
Apr 11, 2023 07:00 am ET
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
TEL AVIV, Israel & RALEIGH, N.C., April 11, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5450(a)(1), the Company was required to maintain a minimum clos
Apr 03, 2023 01:26 pm ET
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C., April 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,500,000 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, series A warrants to purchase up to an aggregate of 1,500,000 ADSs and series B warrants to purchase up to an aggregate of 1,500,000 ADSs. The series A warrants have
Mar 30, 2023 08:00 am ET
RedHill Biopharma Announces $6 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C., March 30, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,500,000 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, series A warrants to purchase up to an aggregate of 1,500,000 ADSs and series B warrants to purchase up to an aggregate of 1,500,000 ADSs at a purchase price of $4.00 per ADS (or ADS equiv
Mar 21, 2023 07:00 am ET
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day treatment course and whose infection is not eradicated based on post-treatment confirmation testing - warranty commitment extends to all commercially insured or non-insured Talicia patients[1]
Mar 16, 2023 06:15 pm ET
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
TEL AVIV, Israel and RALEIGH, NC, March 16, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to implement a ratio change of the Company's American Depositary Shares (ADSs) to its non-traded ordinary shares from the current ratio of one (1) ADS representing ten (10) ordinary shares to a new ratio of one (1) ADS representing four hundred (400) ordinary shares. The anticipated first date of the ratio change is on or about March 23, 2023, and the Company's ADSs will continue to be traded
Mar 08, 2023 06:05 pm ET
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
TEL AVIV, Israel and RALEIGH, NC, March 8, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreement, with a single investor, for the issuance of convertible promissory note in the principal amount of up to $6 million, convertible into American Depositary Shares ("ADS") and warrants to purchase ADSs of the Company, pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended.
Feb 28, 2023 08:01 am ET
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
Feb 16, 2023 08:01 am ET
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
Feb 16, 2023 07:00 am ET
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
UK MHRA scientific advice meeting deems RHB-102 (BEKINDA®) data supportive of submission for approval for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV)RHB-102 UK Marketing Authorisation Application (MAA) submission planned for 2H/23If approved for marketing by the MHRA, RHB-102 could become the first oral 24hr extended-release 5-HT3 antiemetic drug in the UK indicated for the treatment of CINV/RINVTEL-AVIV, Israel and RALEIGH, N.C., Feb. 16, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company,
Feb 06, 2023 06:00 am ET
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
TEL AVIV, Israel and RALEIGH, N.C, Feb. 6, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the extinguishment of all RedHill's debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill's U.S. subsidiary RedHill Biopharma Inc. and HCR dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affiliate of HealthCare Royalty ("HCR").
Jan 27, 2023 07:35 am ET
Thinking about buying stock in WiSA Technologies, Buzzfeed, Applied UV, RedHill Biopharma, or Freight Technologies?
NEW YORK, Jan. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISA, BZFD, AUVI, RDHL, and FRGT.
Jan 26, 2023 06:00 am ET
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
Once issued, the patent is expected to extend protection of RHB-204 to 2041
Jan 03, 2023 11:24 am ET
Thinking about buying stock in Lucira Health, RedHill Biopharma, Plug Power, IQIYI, or Bilibili?
NEW YORK, Jan. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LHDX, RDHL, PLUG, IQ, and BILI.
Jan 03, 2023 06:00 am ET
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Positive data from a U.S. Phase 2 study of once-daily oral RHB-107 (upamostat) in symptomatic COVID-19 published in the peer-reviewed International Journal of Infectious Diseases
Dec 07, 2022 09:45 am ET
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
NEW YORK, NY / ACCESSWIRE / December 7, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL).
Dec 06, 2022 12:36 pm ET
RedHill Biopharma Closes $8.0 Million Underwritten Public Offering
TEL AVIV, Israel and RALEIGH, N.C., Dec. 6, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of an underwritten public offering with gross proceeds to the Company of approximately $8.0 million, before deducting underwriting discounts and other expenses payable by the Company. The offering consisted of 32,000,000 units/pre-funded units consisting of (a) one American Depositary Share ("ADS") (or one pre-funded warrant to purchase one ADS in lieu thereof) and (b) one warrant to purchase on
Dec 02, 2022 08:00 am ET
RedHill Biopharma Prices $8.0 Million Underwritten Public Offering
TEL AVIV, Israel, and RALEIGH, N.C., Dec. 2, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting underwriting discounts and other expenses payable by the Company. The offering consists of 32,000,000 units/pre-funded units consisting of (a) one American Depositary Share ("ADS") (or one pre-funded warrant to purchase one ADS in lieu thereof) and (b) one warrant to
Dec 01, 2022 03:01 pm ET
RedHill Biopharma Announces Proposed Public Offering
TEL AVIV, Israel and RALEIGH, N.C., Dec. 1, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase ADSs (the "Warrants") in an underwritten public offering. Each ADS represents 10 of our ordinary shares, par value NIS 0.01 per share. The Company expects to grant the underwriter a 30-day option to purchase additional ADSs and/or War
Nov 29, 2022 07:00 am ET
RedHill Biopharma Announces Q3/22 Results and Operational Highlights
Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth
Nov 17, 2022 07:30 am ET
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib's potential protective impact on hematological and kidney function following total body irradiation (TBI)
Nov 14, 2022 07:30 am ET
Thinking about buying stock in AMC Entertainment, PDS Biotechnology, RedHill Biopharma, AST SpaceMobile, or SNDL Inc?
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, PDSB, RDHL, ASTS, and SNDL.
Nov 14, 2022 06:00 am ET
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy
Nov 14, 2022 06:00 am ET
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy
Nov 14, 2022 05:00 am ET
RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®
TEL AVIV, Israel and RALEIGH, N.C., Nov. 14, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has reached a non-binding agreement in principle with HCR Collateral Management, LLC ("HCR") with respect to the terms of a transfer of RedHill's rights in Movantik® (naloxegol) to HCR in exchange for the extinguishment of all RedHill's obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill's U.S. subsidiary Re
Nov 07, 2022 08:49 am ET
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated[2] to be between $16.5million to $18.5 million; Operating loss estimated to be in the range of $5.5 million to $7.5 million; Q3/22 cash flow from operating activities is estimated positive for U.S operations, before interest payments[3]
Nov 04, 2022 07:00 am ET
RedHill Presents New Talicia® Data Analyses at Obesity Week 2022
Talicia's efficacy, in this analysis of pooled data from two Phase 3 studies, was unaffected by presence of diabetes or elevated body mass index (BMI); additionally, pharmacokinetic modeling results indicate that intragastric rifabutin exposure was unaffected by elevated patient BMI
Oct 26, 2022 07:00 am ET
RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
Physiologically-Based Pharmacokinetic (PBPK) modeling study of Talicia evaluated intragastric antibiotic exposure, critical for successful H. pylori eradication, comparing low-dose rifabutin 50 mg every 8 hours to generic rifabutin triple therapy 150mg twice a day or 300 mg once a day.
Oct 19, 2022 10:36 am ET
Thinking about buying stock in COMSovereign, RedHill Biopharma, Devon Energy, Kintara Therapeutics, or Zovio?
NEW YORK, Oct. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COMS, RDHL, DVN, KTRA, and ZVO.
Oct 19, 2022 07:00 am ET
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%
Oct 18, 2022 07:00 am ET
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
TEL AVIV, Israel & RALEIGH, N.C., Oct. 18, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announces that on October 12, 2022, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty consecutive business days, the bid price for the Company's American Depositary Shares ("ADSs") had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2). The
Oct 03, 2022 07:00 am ET
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in vitro inhibition of the COVID-19-causing SARS-Cov-2 Omicron BA.5 sub-variant in testing conducted by University of Tennessee Health Sciences Center
Sep 26, 2022 10:55 am ET
Thinking about buying stock in Aditxt, RedHill Biopharma, Corbus Pharmaceuticals, Li Auto, or Kiora Pharmaceuticals?
NEW YORK, Sept. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADTX, RDHL, CRBP, LI, and KPRX.
Aug 17, 2022 08:00 am ET
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
Developed as the first stand-alone standard of care first-line therapy for NTM disease caused by Mycobacterium avium complex (MAC) infection, RHB-204 is currently undergoing a Phase 3 study in the U.S.
Jul 12, 2022 08:00 am ET
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
Talicia® - World Gastro 2022 congress (August 17-18): RedHill invited to give prestigious oral presentation of important data detailing high eradication rates across body mass index (BMI) groups with Talicia, the U.S.'s leading brand for Helicobacter pylori (H. pylori) eradication treatment - invitation sent to researchers with significant recently published clinical findings
Jul 11, 2022 08:30 am ET
Thinking about buying stock in Pliant Therapeutics, Phunware, RedHill Biopharma, Seelos Therapeutics, or HTG Molecular Diagnostics?
NEW YORK, July 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLRX, PHUN, RDHL, SEEL, and HTGM.
Jun 23, 2022 08:30 am ET
Thinking about buying stock in Weber, RedHill Biopharma, Boxed, Hyzon Motors, or Stereotaxis?
NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WEBR, RDHL, BOXD, HYZN, and STXS.
Jun 23, 2022 07:00 am ET
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
Targeting positive cash from operations to start during H2/22[1]
Jun 17, 2022 08:30 am ET
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
May 25, 2022 09:15 am ET
RedHill Presents New Talicia® Data Analyses at DDW 2022
Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H. pylori eradication therapy
May 09, 2022 08:30 am ET
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
TEL AVIV, Israel and RALEIGH, N.C, May 9, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing ten (10) ordinary shares, at a purchase price of $1.42 per ADS (or ADS equivalent), in a registered direct offering. RedHill has also agreed to issue to the investor unregistered privat
Apr 11, 2022 09:00 am ET
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
- Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center
Apr 11, 2022 08:02 am ET
RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib
Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center
Mar 17, 2022 07:59 am ET
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.
Mar 15, 2022 09:00 am ET
RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea
TEL-AVIV, Israel, and RALEIGH, N.C., March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.
Mar 10, 2022 06:00 am ET
RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022
TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.
Mar 01, 2022 08:00 am ET
Feb 17, 2022 08:30 am ET
RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven
TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for the fourth quarter of 2021, including certain estimated unaudited preliminary financial data.
Feb 07, 2022 09:15 am ET
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
TEL AVIV, Israel and RALEIGH, N.C. , Feb. 7, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two recently completed prespecified analyses from the oral opaganib (ABC294640)[1] Phase 2/3 study in hospitalized severe COVID-19. The first analysis showed that opaganib significantly reduced mortality when given to patients who received remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients. A second analysis further showed that opaganib delivere
Jan 14, 2022 07:35 am ET
Thinking about buying stock in Melco Resorts & Entertainment, RedHill Biopharma, Las Vegas Sands, ATI Physical Therapy, or Aqua Metals?
NEW YORK, Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MLCO, RDHL, LVS, ATIP, and AQMS.
Jan 13, 2022 09:35 am ET
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
- In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clearance in the opaganib arm vs. clearance median not reached by end of 14-day treatment in placebo arm (Hazard Ratio 1.34; nominal p-value=0.043, N=437/463)
Jan 06, 2022 08:15 am ET
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
RALEIGH, N.C. and TEL-AVIV, Israel, Jan. 6, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Gaelan Medical Trade LLC ("Gaelan Medical"), a wholly owned subsidiary of the Ghassan Aboud Group (GAG), for Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1], an H. pylori therapy, in the United Arab Emirates (UAE).
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing.
Dec 15, 2021 09:16 am ET
RedHill Announces Additional Insider Buying
RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, Mr. Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares (ADSs) of RedHill since mid-October, 2021, in open-market transactions.
Dec 15, 2021 08:15 am ET
RedHill Biopharma Announces Additional Insider Buying
RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, Mr. Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares (ADSs) of RedHill since mid-October, in open-market transactions.
Dec 14, 2021 07:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com
Dec 09, 2021 11:19 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.
Dec 09, 2021 08:31 am ET
Thinking about buying stock in Aprea Therapeutics, Ocugen, JFrog, RedHill Biopharma, or New Oriental Education & Tech?
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, OCGN, FROG, RDHL, and EDU.
Dec 09, 2021 07:15 am ET
RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori
RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication
Dec 09, 2021 06:00 am ET
RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication
RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the publication in the journal Digestive Diseases and Sciences of a new study entitled "Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data", revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for patients with persistent H. pylori infection despite rising rates of ant
Dec 06, 2021 07:01 am ET
RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations
Unique Mode of Action
Dec 06, 2021 06:00 am ET
Dec 06, 2021 06:00 am ET
Dec 02, 2021 07:01 am ET
RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMI
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI
Dec 02, 2021 06:00 am ET
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announces the publication of a new study entitled "Helicobacter pylori Eradication by Low-Dose Rifabutin Triple Therapy (Talicia®) is Unaffected by High Body Mass Index" in the journal GastroHep, showing the high efficacy of Talicia in eradicating H. pylori irrespective of patient BMI and level of obesity in clinical trials.
Dec 01, 2021 07:02 am ET
RedHill’s Movantik Added To Medicare Formulary
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans
Dec 01, 2021 06:22 am ET
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans
TEL AVIV, Israel and RALEIGH, N.C., Dec. 1, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that one of America's largest payors, serving more than 10 million Americans through multiple Medicare plans, has approved the inclusion of Movantik® (naloxegol), a peripherally acting mu-opioid receptor antagonist (PAMORA) for opioid-induced constipation, as a preferred and unrestricted brand on its National Medicare Part D formulary starting January 1, 2022.
Nov 30, 2021 08:31 am ET
Thinking about buying stock in Cara Therapeutics, RedHill Biopharma, Beyondspring, ATI Physical Therapy, or Co-Diagnostics?
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RDHL, BYSI, ATIP, and CODX.
Nov 30, 2021 07:02 am ET
RedHill Reports 3Q/2021 Financial Results
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
Nov 30, 2021 06:00 am ET
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron
Nov 30, 2021 06:00 am ET
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron
Nov 24, 2021 06:00 am ET
RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021
TEL AVIV, Israel and RALEIGH, N.C., Nov. 24, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its third quarter 2021 financial results and operational highlights on Tuesday, November 30, 2021.
Nov 23, 2021 10:10 am ET
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of the previously announced underwritten public offering of approximately 4.7 million American Depositary Shares ("ADSs") for gross proceeds of approximately $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs wer
Nov 19, 2021 08:00 am ET
RedHill Biopharma Announces Pricing of $15.5 Million Public Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., Nov. 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an underwritten public offering of 4.7 million American Depositary Shares ("ADSs") for gross proceeds of $15.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by RedHill. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs are being offered by RedHill. The closing of the offe
Nov 18, 2021 03:01 pm ET
RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C., Nov. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced an underwritten public offering of American Depositary Shares ("ADSs"). Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs to be sold in the offering will be offered by RedHill. RedHill has granted the underwriter a 30-day option to purchase up to an additional 15 percent of the number of ADSs offered in the public offering.
Nov 15, 2021 07:02 am ET
RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
Nov 15, 2021 06:00 am ET
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care
Nov 15, 2021 06:00 am ET
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care
Nov 09, 2021 06:00 am ET
RedHill Biopharma to Present at H.C. Wainwright 7th Annual Israel Conference and German Equity Forum (EKF) 2021
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill's Chief Business Officer, will present an overview of the Company and host 1-on-1 investor meetings at the following virtual conferences in November:
Nov 08, 2021 07:15 am ET
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days' volume weighted average price (VWAP) ending on the effective date
Nov 08, 2021 06:00 am ET
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a strategic agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for the sale of RedHill's American Depositary Shares ("ADSs") in a private placement of up to $10 million at a 20% premium to the prior 30 trading days' volume weighted average price ("VWAP").
Nov 08, 2021 06:00 am ET
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a strategic agreement with Kukbo Co. Ltd. (Kospi: 001140) ("Kukbo"), a South Korean corporation, for the sale of RedHill's American Depositary Shares ("ADSs") in a private placement of up to $10 million at a 20% premium to the prior 30 trading days' volume weighted average price ("VWAP").
Oct 25, 2021 07:02 am ET
RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021
Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-lineH. pylori therapy over clarithromycin-based regimens
Oct 25, 2021 07:00 am ET
RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021
TEL AVIV, Israel and RALEIGH, N.C., Oct. 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of four new analyses of Phase 3 Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1] and Movantik® (naloxegol)[2] data at the ACG 2021 Annual Scientific Meeting, taking place October 22-27, 2021.
Oct 20, 2021 07:00 am ET
RedHill Biopharma to Present at the BIO-Europe 2021 Conference
TEL AVIV, Israel and RALEIGH, N.C. , Oct. 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a corporate overview at the BIO-Europe Digital Conference, taking place October 25-28, 2021.
Oct 18, 2021 07:02 am ET
RedHill Biopharma Announces Insider Buying
TEL-AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / October 18, 2021 / RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, CFO, Chief Commercial Officer, Chief Business Officer and Chief Corporate & Business Development Officer, collectively purchased approximately 180,000 American Depositary Shares (AD
Oct 18, 2021 07:00 am ET
RedHill Biopharma Announces Insider Buying
TEL-AVIV, Israel & RALEIGH, N.C, Oct. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, CFO, Chief Commercial Officer, Chief Business Officer and Chief Corporate & Business Development Officer, collectively purchased approximately 180,000 American Depositary Shares (ADSs) of RedHill between mid-September and October 15, 2021 in open-market transactions.
Oct 12, 2021 07:02 am ET
RedHill Biopharma Ltd Announces New U.S. Patent for RedHill's Talicia for H.pylori
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034
Oct 12, 2021 07:00 am ET
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034
TEL AVIV, Israel and RALEIGH, N.C., Oct. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of U.S. Patent No. 11,135,172 covering Talicia, its U.S. approved medicine indicated for the treatment of H. pylori infection in adults. This patent reinforces the protection for Talicia through 2034, and the Company plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
Oct 06, 2021 07:02 am ET
RedHill Biopharma Ltd Announces Talicia(R) added to Medi-Cal CDL
RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements
Oct 06, 2021 07:00 am ET
RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 6, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Medi-Cal - California's Medicaid Health Care program covering two million patients - has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1] to its Contract Drug List (CDL) for H. pylori treatment, with no prior authorization required, effective October 1, 2021.
Oct 04, 2021 09:31 am ET
Thinking about buying stock in Xenon Pharmaceuticals, Meritor, RedHill Biopharma, Atea Pharmaceuticals, or Falcon Minerals?
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XENE, MTOR, RDHL, AVIR, and FLMN.
Oct 04, 2021 08:15 am ET
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm vs. 21 deaths in the 134-patient placebo arm; nominal p-value=0.019)
Oct 04, 2021 08:00 am ET
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia showing that treatment with oral opaganib (ABC294640)[1] vs. the placebo-controlled arm resulted in a 62% statistically significant reduction in mortality as well as statistically significant improved outcomes in time to room air and median time to hospital discharge in a group of 251 hospitalized, moder
Oct 04, 2021 08:00 am ET
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia showing that treatment with oral opaganib (ABC294640)[1] vs. the placebo-controlled arm resulted in a 62% statistically significant reduction in mortality as well as statistically significant improved outcomes in time to room air and median time to hospital discharge in a group of 251 hospitalized, moderately s
Sep 23, 2021 07:00 am ET
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
TEL AVIV, Israel and RALEIGH, N.C., Sept. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Aurobindo Pharma USA, Inc. resolving their patent litigation in the U.S. in response to Aurobindo's Abbreviated New Drug Application ("ANDA") seeking approval by the US. Food and Drug Administration ("FDA") to market a generic vers
Sep 14, 2021 08:15 am ET
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, NC, Sept. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in hospitalized patients with severe COVID-19 pneumonia.
Sep 13, 2021 07:02 am ET
RHB-107 P2/3 COVID-19 Study South Africa Approval
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
Sep 13, 2021 07:00 am ET
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care
Sep 13, 2021 07:00 am ET
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care
Sep 07, 2021 07:02 am ET
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
COVID-19 and long COVID patients are at increased risk of developing kidney damage-Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model-Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to end-stage renal failure-Opaganib is a novel, late clinical-stage oral pill drug candidate with dual anti-inflammatory an
Sep 07, 2021 07:00 am ET
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results of a new preclinical study demonstrating opaganib's (ABC294640)[1] efficacy in significantly decreasing renal fibrosis in a unilateral ureteral obstruction-induced renal interstitial fibrosis model. Reports suggest that over 20% of hospitalized COVID-19 patients experience acute renal failure[2].
Sep 07, 2021 07:00 am ET
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results of a new preclinical study demonstrating opaganib's (ABC294640)[1] efficacy in significantly decreasing renal fibrosis in a unilateral ureteral obstruction-induced renal interstitial fibrosis model. Reports suggest that over 20% of hospitalized COVID-19 patients experience acute renal failure[2].
Sep 07, 2021 06:02 am ET
RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
Sep 07, 2021 06:00 am ET
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik® (naloxegol) Phase 3 study data demonstrating rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged ≥ 65 and across both low and high dose opioid therapy.
Sep 07, 2021 06:00 am ET
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik® (naloxegol) Phase 3 study data demonstrating rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged ≥ 65 and across both low and high dose opioid therapy.
Sep 02, 2021 10:35 am ET
RedHill to Present at HCW & Cantor Conferences
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
Sep 02, 2021 10:00 am ET
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
TEL AVIV, Israel and RALEIGH, NC, Sept. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in September:
Aug 31, 2021 08:30 am ET
Thinking about buying stock in AC Immune, Designer Brands, Rekor Systems, RedHill Biopharma, or Corsair Gaming?
NEW YORK, Aug. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACIU, DBI, REKR, RDHL, and CRSR.
Aug 27, 2021 09:31 am ET
Thinking about buying stock in Chembio Diagnostics, Mogu, Adial Pharmaceuticals, Globalstar, or RedHill Biopharma?
NEW YORK, Aug. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, MOGU, ADIL, GSAT, and RDHL.
Aug 26, 2021 09:31 am ET
Thinking about buying stock in Beyondspring, RedHill Biopharma, Glory Star New Media, CarGurus, or Kopin?
NEW YORK, Aug. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYSI, RDHL, GSMG, CARG, and KOPN.
Aug 26, 2021 07:30 am ET
RedHill Reports Second Quarter 2021 Results
TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / August 26, 2021 / RedHill Biopharma Ltd. (Nasdaq:RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter ended June 30, 2021.
Aug 26, 2021 07:00 am ET
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /CNW/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter ended June 30, 2021.
Aug 26, 2021 07:00 am ET
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter ended June 30, 2021.
Aug 26, 2021 06:30 am ET
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
Aug 26, 2021 06:00 am ET
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant concentrations.
Aug 26, 2021 06:00 am ET
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant concentrations.
Aug 23, 2021 07:05 am ET
RedHill Announces Two New U.S. Patents
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
Aug 23, 2021 07:00 am ET
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
TEL AVIV, Israel and RALEIGH, N.C., Aug. 23, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029.
Aug 23, 2021 07:00 am ET
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
TEL AVIV, Israel and RALEIGH, N.C., Aug. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029.
Aug 19, 2021 07:00 am ET
RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
TEL AVIV, Israel and RALEIGH, NC, Aug. 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its second quarter 2021 financial results and operational highlights on Thursday, August 26, 2021.
Jul 22, 2021 09:45 am ET
RedHill Settles Movantik(R) Apotex Patent Litigation
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
Jul 22, 2021 09:19 am ET
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
TEL AVIV, Israel and RALEIGH, NC, July 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. and Apotex Corp. ("Apotex") resolving their patent litigation in the U.S. in response to Apotex's Abbreviated New Drug Application ("ANDA") seeking approval by the US. Food and Drug Administration ("FDA") to market a gene
Jul 20, 2021 08:00 am ET
RedHill Extends Talicia Commercial Coverage
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
Jul 20, 2021 07:00 am ET
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
TEL-AVIV, Israel and RALEIGH, N.C., July 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that OptumRx, part of the UnitedHealth Group - a leader in healthcare coverage, partnered with more than 1.3 million healthcare professionals and 6,500 hospitals, has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1] to its Commercial Formulary as an unrestricted brand for H. pylori treatment, effective July 1, 2021.
Jul 19, 2021 10:15 am ET
RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Jul 19, 2021 07:00 am ET
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
TEL AVIV, Israel and RALEIGH, NC, July 19, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.
Jul 19, 2021 07:00 am ET
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
TEL AVIV, Israel and RALEIGH, NC, July 19, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.
Jul 13, 2021 11:00 am ET
RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans
TEL-AVIV, Israel and RALEIGH, N.C., July 13, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that one of America's largest payors, serving many Blue Cross and Blue Shield Plans and more than 30 million members, has added Movantik® (naloxegol), a peripherally acting mu-opioid receptor antagonist (PAMORA) for opioid-induced constipation (OIC), as a preferred brand with no restrictions to a National Formulary and as a preferred brand on its other commercial formularies starting July 1, 2021.
Jun 28, 2021 07:00 am ET
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
TEL AVIV, Israel and RALEIGH, N.C., June 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva®, ABC294640)[1].
Jun 28, 2021 07:00 am ET
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
TEL AVIV, Israel and RALEIGH, N.C., June 28, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva®, ABC294640)[1].
Jun 21, 2021 07:00 am ET
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).
Jun 21, 2021 07:00 am ET
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).
Jun 09, 2021 07:00 am ET
RedHill Biopharma to Present at the BIO Digital International Convention
TEL AVIV, Israel and RALEIGH, N.C., June 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a corporate overview at the BIO Digital International Convention, taking place June 14-18, 2021.
May 27, 2021 07:15 pm ET
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
May 27, 2021 07:15 pm ET
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
Feb 23, 2021 06:03 am ET
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with severe COVID-19 to the U.S., following U.S. Food and Drug Administration (FDA) review of the data from the U.S. Phase 2 study of opaganib and receipt of its recommendations.
Feb 18, 2021 06:00 am ET
RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) ("Cosmo") to manufacture two key products; RedHill's largest selling product in the U.S., Movantik®, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Feb 17, 2021 06:00 am ET
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient was dosed in its U.S. Phase 2/3 study of orally-administered RHB-107 (upamostat)[1], an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
Feb 09, 2021 06:00 am ET
RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences
TEL AVIV, Israel and RALEIGH, N.C., Feb. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in February:
Jan 29, 2021 06:00 am ET
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib[1] in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
Jan 28, 2021 06:27 am ET
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a manufacturing agreement with Cosmo Pharmaceuticals NV (SIX: COPN) ("Cosmo") to further expand manufacturing capacity for opaganib (Yeliva®, ABC294640)[1], to address prospective demand subsequent to potential global emergency use authorizations.
Jan 14, 2021 01:13 pm ET
RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) of the Company, at a price to the public of $7.84 per ADS. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company.
Jan 12, 2021 07:51 am ET
RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million
TEL AVIV, Israel and RALEIGH, N.C., Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,188,776 American Depositary Shares (ADSs) of the Company, at a price to the public of $7.84 per ADS, less underwriting discounts and commissions. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. The closing of the offering i
Jan 11, 2021 03:35 pm ET
RedHill Biopharma Announces $10 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C., Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,275,510 American Depositary Shares (ADSs) of the Company, at a price to the public of $ $7.84 per ADS, less underwriting discounts and commissions. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. The clo
Jan 11, 2021 06:00 am ET
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Jan 11, 2021 06:00 am ET
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Jan 06, 2021 06:00 am ET
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) – a rare disease for which there is no FDA-approved first-line therapy.
Dec 31, 2020 08:30 am ET
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals.
Dec 31, 2020 08:30 am ET
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals.
Dec 22, 2020 06:00 am ET
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
TEL AVIV, Israel and RALEIGH, N.C., Dec. 22, 2020 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a second unanimous recommendation to continue, following a second independent Data Safety Monitoring Board (DSMB) safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 155 patients treated for 14 days.
Dec 22, 2020 06:00 am ET
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
TEL AVIV, Israel and RALEIGH, N.C., Dec. 22, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a second unanimous recommendation to continue, following a second independent Data Safety Monitoring Board (DSMB) safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 155 patients treated for 14 day
Dec 15, 2020 08:30 am ET
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
TEL AVIV, Israel and RALEIGH, N.C., Dec. 15, 2020 /CNW/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study within which opaganib, a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) demonstrating a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome (ARDS) – a preclinical animal model designed to measure thrombotic (blood clot) risks.
Dec 15, 2020 08:30 am ET
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
TEL AVIV, Israel and RALEIGH, N.C., Dec. 15, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study within which opaganib, a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) demonstrating a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome (ARDS) – a preclinical animal model designed to measure thrombotic (blood clot) risks.
Dec 14, 2020 07:00 am ET
RedHill Biopharma Added to NASDAQ Biotechnology Index
TEL AVIV, Israel and RALEIGH, N.C., Dec. 14, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NBI will become effective prior to market open on Monday, December 21, 2020.
Dec 07, 2020 06:00 am ET
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans
TEL AVIV, Israel and RALEIGH, N.C., Dec. 7, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has increased unrestricted national and regional commercial coverage for Talicia® (omeprazole magnesium, amoxicillin and rifabutin)[1] to more than 40 million additional Americans.
Nov 25, 2020 09:36 am ET
Nov 23, 2020 07:00 am ET
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December:
Nov 20, 2020 07:00 am ET
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
TEL AVIV, Israel and RALEIGH, N.C., Nov. 20, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) – a rare disease for which there is no FDA-approved first-line therapy.
Nov 19, 2020 06:00 am ET
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Nov. 19, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a pre-scheduled safety review by an independent Data and Safety Monitoring Board (DSMB). The DSMB's recommendation is based on an unblinded analysis of safety data from the first 70 patients treated for 14 days.
Nov 17, 2020 06:00 am ET
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease
TEL AVIV, Israel and RALEIGH, N.C., Nov. 17, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered RHB-107 (upamostat)[1] in patients with symptomatic COVID-19 who do not require hospitalization.
Nov 16, 2020 09:13 am ET
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
TEL AVIV, Israel and RALEIGH, NC, Nov. 16, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has completed enrollment of the last patient in the study. The study is not powered for statistical significance. Topline data is expected in the coming weeks.
Nov 13, 2020 07:00 am ET
RedHill Biopharma to Present at German Equity Forum 2020
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview and host 1-on-1 investor meetings...
Nov 12, 2020 07:00 am ET
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the third quarter ended September 30, 2020. Dror Ben-Asher, RedHill’s...
Nov 05, 2020 07:00 am ET
RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, November 12, 2020....
Nov 04, 2020 10:30 am ET
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent...
Oct 26, 2020 09:00 am ET
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that new data supporting the use of Talicia®1 as a first-line therapy for eradication of H. pylori in adults was presented at...
Oct 14, 2020 11:00 am ET
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RHB-204 for the treatment of...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.